Evidence map›Paper›PMID 22476389›Full record

ArticleEuropean journal of clinical pharmacology2012

Association of long-term adherence to evidence-based combination drug therapy after acute myocardial infarction with all-cause mortality. A prospective cohort study based on claims data.

Jutta Kuepper-Nybelen, Martin Hellmich, Sascha Abbas, Peter Ihle, Reinhard Griebenow, Ingrid Schubert

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jutta Kuepper-NybelenDepartment of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne, Herderstrasse 52, 50931, Cologne, Germany. jutta.kuepper-nybelen@uk-koeln.de
Martin Hellmich
Sascha Abbas
Peter Ihle
Reinhard Griebenow
Ingrid Schubert

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo determine long-term adherence to evidence-based secondary preventive combination pharmacotherapy in survivors of acute myocardial infarction (AMI) and to investigate the association between adherence to recommended therapy and all-cause mortality in claims data.

methodsProspective cohort study based on claims data of an 18.75 % random sample of all persons insured with the local statutory health insurance fund AOK Hesse. Study population included patients with hospital discharge diagnoses of AMI between 2001 and 2005 excluding those who died within the first 30 days after AMI or who had been hospitalised with an AMI in the previous 2 years. A total of 3,008 patients were followed up until death, cancellation of insurance, or the end of the study period on 31 December 2007, whichever came first (median follow-up: 4.2 years).

resultsDrug adherence to single drug groups as determined by proportion of days covered ≥80 % was 21.8 % for antiplatelet drugs, 9.4 % for beta-blockers, 45.6 % for ACE inhibitors or angiotensin II receptor blockers and 45.1 % for lipid-lowering drugs. A total of 924 (39.7 %) patients met our definition of guideline adherence: Drugs available from three of four relevant drug groups on the same day for at least 50 % of the observation time. Of the patients adhering to the guidelines, 17.3 % died and of the non-adherents, 32.4 % died. All-cause mortality was 28 % lower for guideline-adherent patients than for the non-adherent group (adjusted HR 0.72, 95 % CI 0.60-0.86).

conclusionsIn everyday practice, post AMI patients benefit from guideline-oriented treatment, but the percentage of adherent patients should be improved.

Indexed as

Drug MonitoringAdrenergic beta-AntagonistsAgedAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsCohort StudiesDrug Therapy, CombinationFemaleFollow-Up StudiesGermanyGuideline AdherenceHumansHypolipidemic AgentsMaleMyocardial InfarctionPatient DischargeAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsHypolipidemic AgentsPlatelet Aggregation Inhibitors

Identifiers

PMID22476389

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.